This Phase II study is designed to determine the safety, tolerability, pharmacokinetics, and effects of EVP-0962 on levels of amyloid in the cerebrospinal fluid of healthy people and those with mild cognitive impairment (MCI) or early Alzheimer's disease.
|Min Age||Max Age||Gender||Healthy Volunteers|
Participants with MCI or Early Alzheimer's Disease
This study of the experimental drug EVP-0962 will be conducted in two parts. The first part will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of escalating EVP-0962 doses (10 mg, 50 mg, 100 mg, and 200 mg) for 14 days in healthy subjects. The second part will evaluate the same outcomes following once-daily administration for 14 days in participants with MCI or early Alzheimer's disease. EVP-0962 modulates an enzyme, gamma secretase, involved in the processing of amyloid and its toxic amyloid-beta 1-42 peptide, a key component of amyloid plaques in the brains of people with Alzheimer's disease.
|Map Marker||City||State||Zip Code||Status||Primary Contact|
Geolocation is 34.1527251, -118.2117257
EnVivo Pharmaceuticals, Inc.
PAREXEL International Corp.
David S. Han, MD
Glendale Adventist Medical Center